In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Folks on GLP-1 drugs can expect to maintain their weight loss if they have a disruption in access, as long as they’ve also ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Learn how the benefits of GLP-1s may be outweighed by the risks.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...